兩項試驗正在計劃之中，將評估前列腺癌診斷以及鑒別無痛和進展性病變的蛋白質(zhì)模式識別系統(tǒng)。目的是研制開發(fā)更加有效的前列腺癌血液檢測方法。

一種叫做ProteomeDx的蛋白質(zhì)識別系統(tǒng)是由Correlogic系統(tǒng)集團研制開發(fā)用于檢測前列腺癌。該公司在這兩項試驗中與以下機構進行合作：健康科學大學統(tǒng)一服務部(USU, also in Bethesda)、Jackson軍事醫(yī)學進步基金會(Rockville, MD, USA)、前列腺癌研究中心、USU和該基金會的外科研究項目。USU是得到認可的聯(lián)邦醫(yī)學院，由美國國防部主辦。Henry M. Jackson基金會是得到美國國會批準非營利組織，支持USU以及整個軍事醫(yī)學領域的軍事教育和科研。

第一項試驗將涉及2000例明確診斷為前列腺癌的患者。第二項試驗將重點放在接受激進的前列腺切除手術的患者，以確定Correlogic公司的方法和技術能否被進一步用于區(qū)別大多數(shù)男性的前列腺癌是進展性還是無痛性的。Correlogic還研制開發(fā)了OvaCheck血液檢測用于檢查早期卵巢癌，這是經(jīng)過確認的病情的終末階段。

Correlogic系統(tǒng)總裁兼首席執(zhí)行官Peter J.Levine說：“確定進展性和無痛性前列腺癌意味著生命與死亡、治療與無須治療之間的區(qū)別?！?/P>

New Studies of Prostate Cancer Blood Test
 
Two studies are being planned that will examine the use of a protein pattern recognition system for use in diagnosing prostate cancer and for use in distinguishing between indolent and aggressive disease. The goal is to develop a more-effective blood test for the detection of prostate cancer.

A protein pattern recognition system called ProteomeDx has been developed by Correlogic Systems, Inc. (Bethesda, MD, USA) for detecting prostate cancer. The company is collaborating on the two studies with the Uniformed Services University of the Health Sciences (USU, also in Bethesda), the Henry M. Jackson Foundation for the Advancement of Military Medicine (Rockville, MD, USA), and the Center for Prostate Disease Research, a program of the department of surgery at USU and the Foundation. The USU is a fully accredited federal school of medicine, operated by the U.S. Department of Defense. The Henry M. Jackson Foundation is a not-for-profit organization authorized by the U.S. Congress to support military education and research at USU and throughout the military medical community.

The first study will involve up to 2,000 men with specified prostate cancer conditions. The second study will focus on men undergoing radical prostatectomy to determine if Correlogic’s approach and technology can be extended to distinguish between aggressive and indolent disease. Currently there is no effective prospective test for determining the aggressiveness of prostate cancer in most men. Correlogic also developed the OvaCheck blood test for the early detection of ovarian cancer, which is in the final stages of an extensive validation process.

“The determination of aggressive versus indolent prostate cancer means the difference between life and death, and necessary versus unnecessary treatment,” observed Peter J. Levine, president and CEO of Correlogic Systems.